TD Cowen analyst Tara Bancroft reinstated coverage of Day One Biopharmaceuticals (DAWN) with a Buy rating and $34 price target following the completed the acquisition of Mersana Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals: Ojemda Outperformance and Advancing Pipeline Support Overweight Rating
- Video: Financials weighed down by Trump attacks on Fed, credit card rates
- Morning Movers: Sun Country jumps after deal to be bought by Allegiant
- Day One Biopharmaceuticals Announces Strong OJEMDA Revenue Outlook
- Day One reports preliminary FY25 Ojemda net product revenue of $155.4M